Advancing Therapeutic Protein Discovery and Development through Comprehensive Computational and Biophysical Characterization

被引:39
作者
Gentiluomo, Lorenzo [1 ,2 ,10 ]
Svilenov, Hristo L. [2 ]
Augustijn, Dillen [3 ]
El Bialy, Inas [2 ]
Greco, Maria Laura [4 ]
Kulakova, Alina [5 ]
Indrakumar, Sowmya [5 ]
Mahapatra, Sujata [6 ]
Morales, Marcello Martinez [4 ]
Pohl, Christin [6 ]
Roche, Aisling [7 ]
Tosstorff, Andreas [2 ]
Curtis, Robin [7 ]
Derrick, Jeremy P. [8 ]
Norgaard, Allan [6 ]
Khan, Tarik A. [9 ]
Peters, Gunther H. J. [5 ]
Pluen, Alain [7 ]
Rinnan, Asmund [3 ]
Streicher, Werner W. [6 ]
van der Walle, Christopher F. [4 ]
Uddin, Shahid [4 ,11 ]
Winter, Gerhard [2 ]
Roessner, Dierk [1 ]
Harris, Pernille [5 ]
Friess, Wolfgang [2 ]
机构
[1] Wyatt Technol Europe GmbH, Hochstr 18, D-56307 Dernbach, Germany
[2] Ludwig Maximilians Univ Muenchen, Dept Pharm Pharmaceut Technol & Biopharmaceut, Butenandtstr 5, D-81377 Munich, Germany
[3] Univ Copenhagen, Fac Sci, Dept Food Sci, Rolighedsvej 26, DK-1958 Frederiksberg, Denmark
[4] AstraZeneca, Dosage Form Design & Dev, Sir Aaron Klug Bldg,Granta Pk, Cambridge CB21 6GH, England
[5] Tech Univ Denmark, Dept Chem, Kemitorvet 207, DK-2800 Lyngby, Denmark
[6] Novozymes AS, Krogshoejvej 36, DK-2880 Bagsvaerd, Denmark
[7] Univ Manchester, Manchester Inst Biotechnol, Sch Chem Engn & Analyt Sci, 131 Princess St, Manchester M1 7DN, Lancs, England
[8] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Sch Biol Sci, Oxford Rd, Manchester M13 9PT, Lancs, England
[9] F Hoffmann La Roche Ltd, Pharma Tech Dev Biol Europe, Pharmaceut Dev & Supplies, Grenzacherstr 124, CH-4070 Basel, Switzerland
[10] Coriolis Pharma Res GmbH, FraunhoferstraBe 18B, D-82152 Planegg, Germany
[11] Immunocore Ltd, 101 Pk Dr, Milton OX14 4RY, Abingdon, England
基金
英国生物技术与生命科学研究理事会; 欧盟地平线“2020”;
关键词
therapeutic proteins; protein formulation; developability assessment; protein characterization; MONOCLONAL-ANTIBODY; DEVELOPABILITY ASSESSMENT; CHEMICAL DENATURATION; STRUCTURAL BASIS; STABILITY; VISCOSITY; TOOL; SOLUBILITY; LIPASE; VALUES;
D O I
10.1021/acs.molpharmaceut.9b00852
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Therapeutic protein candidates should exhibit favorable properties that render them suitable to become drugs. Nevertheless, there are no well-established guidelines for the efficient selection of proteinaceous molecules with desired features during early stage development. Such guidelines can emerge only from a large body of published research that employs orthogonal techniques to characterize therapeutic proteins in different formulations. In this work, we share a study on a diverse group of proteins, including their primary sequences, purity data, and computational and biophysical characterization at different pH and ionic strength. We report weak linear correlations between many of the biophysical parameters. We suggest that a stability comparison of diverse therapeutic protein candidates should be based on a computational and biophysical characterization in multiple formulation conditions, as the latter can largely determine whether a protein is above or below a certain stability threshold. We use the presented data set to calculate several stability risk scores obtained with an increasing level of analytical effort and show how they correlate with protein aggregation during storage. Our work highlights the importance of developing combined risk scores that can be used for early stage developability assessment. We suggest that such scores can have high prediction accuracy only when they are based on protein stability characterization in different solution conditions.
引用
收藏
页码:426 / 440
页数:15
相关论文
共 63 条
[1]  
[Anonymous], 2005, JMP BASIC UNIVARIATE
[2]  
Berman H. M., 2006, PROTEIN DATA BANK 19, VF, P675, DOI DOI 10.1107/97809553602060000722
[3]   Examination of Thermal Unfolding and Aggregation Profiles of a Series of Developable Therapeutic Monoclonal Antibodies [J].
Brader, Mark L. ;
Estey, Tia ;
Bai, Shujun ;
Alston, Roy W. ;
Lucas, Karin K. ;
Lantz, Steven ;
Landsman, Pavel ;
Maloney, Kevin M. .
MOLECULAR PHARMACEUTICS, 2015, 12 (04) :1005-1017
[4]   A MODEL FOR INTERFACIAL ACTIVATION IN LIPASES FROM THE STRUCTURE OF A FUNGAL LIPASE-INHIBITOR COMPLEX [J].
BRZOZOWSKI, AM ;
DEREWENDA, U ;
DEREWENDA, ZS ;
DODSON, GG ;
LAWSON, DM ;
TURKENBURG, JP ;
BJORKLING, F ;
HUGEJENSEN, B ;
PATKAR, SA ;
THIM, L .
NATURE, 1991, 351 (6326) :491-494
[5]   Use of microcalorimetry and its correlation with size exclusion chromatography for rapid screening of the physical stability of large pharmaceutical proteins in solution [J].
Burton, Lori ;
Gandhi, Rajesh ;
Duke, Gerald ;
Paborji, Mehdi .
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2007, 12 (03) :265-273
[6]   BLAST plus : architecture and applications [J].
Camacho, Christiam ;
Coulouris, George ;
Avagyan, Vahram ;
Ma, Ning ;
Papadopoulos, Jason ;
Bealer, Kevin ;
Madden, Thomas L. .
BMC BIOINFORMATICS, 2009, 10
[7]   Potent antibody therapeutics by design [J].
Carter, PJ .
NATURE REVIEWS IMMUNOLOGY, 2006, 6 (05) :343-357
[8]   Design of therapeutic proteins with enhanced stability [J].
Chennamsetty, Naresh ;
Voynov, Vladimir ;
Kayser, Veysel ;
Helk, Bernhard ;
Trout, Bernhardt L. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (29) :11937-11942
[9]   AGGRESCAN:: a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides [J].
Conchillo-Sole, Oscar ;
de Groot, Natalia S. ;
Aviles, Francesc X. ;
Vendrell, Josep ;
Daura, Xavier ;
Ventura, Salvador .
BMC BIOINFORMATICS, 2007, 8 (1)
[10]   Weak Interactions Govern the Viscosity of Concentrated Antibody Solutions: High-Throughput Analysis Using the Diffusion Interaction Parameter [J].
Connolly, Brian D. ;
Petry, Chris ;
Yadav, Sandeep ;
Demeule, Barthelemy ;
Ciaccio, Natalie ;
Moore, Jamie M. R. ;
Shire, Steven J. ;
Gokarn, Yatin R. .
BIOPHYSICAL JOURNAL, 2012, 103 (01) :69-78